BAM
CDAK

Belpointe Asset Management’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Belpointe Asset Management’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,506
Closed -$996 – 3898
2022
Q4 		$996 Buy
+2,506
New +$1.65K ﹤0.01% 3438

Other funds holding CDAK

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FA
Forefront Analytics West Conshohocken, Pennsylvania $110M AUM 18.54% 1-Year Est. Return
PM
Parametrica Management Wanchai, Hong Kong $88M AUM 48.84% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Belpointe Asset Management's CDAK Position: Q1 2023 in Review

Belpointe Asset Management sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q1 2023, closing a stake of 2,506 shares — an estimated $996 sold.

Belpointe Asset Management first reported a position in CDAK in Q4 2022 and held it in 1 quarter. The position peaked at $996 in Q4 2022. 27 funds tracked by Wall St. Rank hold CDAK as of Q1 2023.

  • Belpointe Asset Management reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 2,506 Codiak BioSciences, Inc. Common Stock shares in Q1 2023, an estimated $996.
  • Belpointe Asset Management first reported a position in Codiak BioSciences, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Belpointe Asset Management's Codiak BioSciences, Inc. Common Stock position peaked at $996 in Q4 2022.
  • 27 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q1 2023.

Based on Belpointe Asset Management's 13F filing for Q1 2023, filed 15 May 2023.